# Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

Source: https://onco.cc/trials/nct04692103/  
OnCo record `nct04692103` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Fluoroestradiol F-18 and Fludeoxyglucose F-18 in Breast cancer, run by University of Washington, active and no longer recruiting.

## Summary

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy is a phase 2 interventional study registered as NCT04692103 by University of Washington, with 2 participants planned, started 2021-07-10 and due to reach its primary completion in 2021-10-01. Interventions recorded: F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Laboratory Biomarker Analysis. Conditions recorded: Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7.

Linked to the drug Fludeoxyglucose F-18 because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04692103
- Phase: 2
- Setting: Serial [F-18] Fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-targeted Therapy
- Sponsor: University of Washington
- Enrolled: 2

## Sources

- ClinicalTrials.gov NCT04692103: https://clinicaltrials.gov/study/NCT04692103

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Fludeoxyglucose F-18 (FDG)](https://onco.cc/drugs/fludeoxyglucose-f18/), [Fluoroestradiol F-18 (FES PET)](https://onco.cc/drugs/fluoroestradiol-f18/)

---
JSON: https://onco.cc/api/v1/entities/nct04692103.json